# A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors

> **NCT06764836** · PHASE1 · RECRUITING · sponsor: **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.** · enrollment: 108 (estimated)

## Conditions studied

- Advanced Solid Tumors
- HCC

## Interventions

- **DRUG:** IMM27M
- **DRUG:** IMM2510

## Key facts

- **NCT ID:** NCT06764836
- **Lead sponsor:** ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-23
- **Primary completion:** 2026-01-27
- **Final completion:** 2026-01-27
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06764836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06764836, "A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06764836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*